State of Wisconsin Investment Board’s RAPT Therapeutics RAPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-2,526
Closed -$181K 2369
2024
Q1
$181K Sell
2,526
-301
-11% -$41.8K ﹤0.01% 2083
2023
Q4
$562K Sell
2,827
-577
-17% -$71.4K ﹤0.01% 1662
2023
Q3
$453K Buy
3,404
+319
+10% +$52.1K ﹤0.01% 1847
2023
Q2
$461K Sell
3,085
-951
-24% -$148K ﹤0.01% 1855
2023
Q1
$593K Buy
4,036
+439
+12% +$88.8K ﹤0.01% 1792
2022
Q4
$570K Buy
3,597
+569
+19% +$91.1K ﹤0.01% 1848
2022
Q3
$583K Buy
3,028
+315
+12% +$59.6K ﹤0.01% 1895
2022
Q2
$396K Sell
2,713
-850
-24% -$113K ﹤0.01% 2189
2022
Q1
$627K Buy
3,563
+500
+16% +$94.4K ﹤0.01% 1742
2021
Q4
$900K Hold
3,063
﹤0.01% 1486
2021
Q3
$761K Buy
3,063
+1,088
+55% +$288K ﹤0.01% 1536
2021
Q2
$502K Hold
1,975
﹤0.01% 1688
2021
Q1
$351K Hold
1,975
﹤0.01% 1729
2020
Q4
$312K Sell
1,975
-250
-11% -$54.4K ﹤0.01% 1826
2020
Q3
$573K Buy
+2,225
New +$494K ﹤0.01% 1431

Other funds holding RAPT

State of Wisconsin Investment Board's RAPT Position: Q2 2024 in Review

State of Wisconsin Investment Board sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 2,526 shares — an estimated $181K sold.

State of Wisconsin Investment Board first reported a position in RAPT in Q3 2020 and held it in 15 quarters. The position peaked at $900K in Q4 2021. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • State of Wisconsin Investment Board reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • State of Wisconsin Investment Board sold 2,526 RAPT Therapeutics shares in Q2 2024, an estimated $181K.
  • State of Wisconsin Investment Board first reported a position in RAPT Therapeutics in Q3 2020 and held it in 15 quarters.
  • State of Wisconsin Investment Board's RAPT Therapeutics position peaked at $900K in Q4 2021.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on State of Wisconsin Investment Board's 13F filing for Q2 2024, filed 14 Aug 2024.